Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic

NCT04431258 is registered in ClinicalTrials.gov with Ability Pharmaceuticals SL as lead sponsor.

NCT NCT04431258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04431258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic
Lead sponsor
Ability Pharmaceuticals SL
Phase
Phase 1/2
Overall status
Completed
Start date
May 6, 2021
Completion date
January 10, 2024
Enrollment
150 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer